Dr. Len Calabrese gives advice on vaccinating adult patients with rheumatic disease

He highlights safety protocols and advises on recommended vaccines in rheumatology practice.

Promising drugs line up for lupus treatment

Lupus drugs in late-stage development seek to address unmet needs, notably in lupus nephritis.

Expert shares tips for TNF-alpha inhibitor use in special populations

LAS VEGAS – Optimizing anti-TNF-alpha treatment starts with recognizing there is a loss of response over time, Dr. Kerdel said.

Narrowband UVB phototherapy an effective treatment for psoriasis

LAS VEGAS – Home-based UVB phototherapy is gaining in popularity and is comparable with in-office UVB in terms of accuracy and efficacy.

Serum urate level governs management of difficult-to-treat gout

LAS VEGAS – Insufficient dosing of urate lowering therapy may be a reason for perceived treatment resistance.

Take drug, patient-level factors into account for when to end antiresorptive therapy

LAS VEGAS – The agent and individual patient factors may affect the duration of treatment and the approach to resuming therapy.

Guide to the guidelines: Biologics for psoriasis

Dr. April Armstrong highlights key messages in the AAD’s guidelines for the use of biologics to treat psoriasis.

Ixekizumab psoriasis outcomes, sliced and diced

WAIKOLOA, HAWAII – The jaw-dropping NNT to achieve complete skin clearance: 2.6 patients.

What’s new with adalimumab? Plenty

WAIKOLOA, HAWAII – New information includes reassuring new long-term, real-world safety data, plus a simple early predictor of PASI 75 response.

Guselkumab tops secukinumab over 48 weeks for plaque psoriasis

CAYMAN ISLANDS – In both groups, the PASI 90 increased similarly in the first month, but was consistently higher in the guselkumab group at week 12 and after.

Pages